Hydralazine
Hydrazinophthalazine Derivatives
- Drug class
- Hydrazinophthalazine Derivatives
- Availability
- Prescription only
- Routes
- Oral, Intramuscular, Intravenous
- Markets covered
- 3
- Products on record
- 21
Overview
Hydralazine is an active pharmaceutical ingredient in the Hydrazinophthalazine Derivatives group (C02DB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 10 | December 26, 2025 |
| GB United Kingdom | MHRA | 7 | May 1, 2026 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
USUnited States· FDA
10 products
Uses
INDICATIONS AND USAGE
Essential hypertension, alone or as an adjunct.
How to take
GBUnited Kingdom· MHRA
7 products
Uses
Hydralazine is indicated for: 1) Moderate to severe hypertension as an adjunct to other anti-hypertensive agents. Due to the complementary mechanism of action the combination of hydralazine with b- blockers and diuretics may enable antihypertensive efficacy at lower dose levels and counteract accompanying hydralazine effects such as reflex tachycardia and oedema.
2) As supplementary medication for use in combination with long-acting nitrates in moderate to severe chronic congestive cardiac failure in patients in whom optimal doses of conventional therapy have proved insufficient.
How to take
CACanada· Health Canada
4 products
Uses
, toxemia of pregnancy or pre-eclampsia). 1 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatric patients or patients with marked renal damage may require a lower dosage.
How to take
Drug interactions
Known interactions involving Hydralazine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 282. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 024ac6b8-5ce0-44… · revised July 1, 2025 [PDF]
- [2]MHRA (UK) · PL001420499 · revised May 1, 2026
- [3]Health Canada (DPD) · 02406012 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.